Document is current

Article History

Received: 7 February 2025

Accepted: 15 May 2025

First Online: 31 May 2025

Declarations

:

: NHS trusts employing Anna Olsson-Brown, Ankit Jain, Ricky Frazer, David Farrugia and Judith Carser received fees from Bristol Myers Squibb for data collection in relation to this study. In addition, Anna Olsson-Brown has previously received honoraria and/or congress support from Bristol Myers Squibb, MSD, Astra Zeneca, Ipsen, Roche, Regeneron, GSK, Eisai and Chugai; Ankit Jain has received honoraria and/or congress support from MSD, Merck, Takeda, Pfizer, Astra Zeneca and Roche; Ricky Frazer has received speaking and/or advisory fees from Bristol Myers Squibb, Eisai, Ewopharma, Ipsen, Merck, MSD, Novartis, Pfizer, Pierre Fabre, Recordati, Roche, Sanofi and Servier; David Farrugia is employed by Merck Sharpe and Dohme (since May 2024) and Judith Carser declares no additional competing interests. John Houghton and Ruth Lewis are employees of Health Economics and Outcomes Research Ltd, which received fees from Bristol Myers Squibb in relation to this study. Simon D’Mello and Gabrielle Emanuel are employees of Bristol Myers Squibb.

: Approval was obtained from the Health Research Authority (HRA) and Health and Care Research Wales (HCRW) (IRAS Project ID: 284489), with minor amendments submitted and approved on 19 October 2021 and 14 December 2021, respectively. This study did not require research ethics committee (REC) review or informed patient consent because it used previously collected data that was not identifiable outside of the direct care team (Reference: 21/PR/0474).